Patients with Limited Stage Small-Cell Lung Cancer (LS-SCLC) research hub

A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with Limited Stage Small-Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy (ADRIATIC)

This study looks at whether adding immunotherapy drugs helps people with limited-stage small-cell lung cancer. Researchers want to see if giving durvalumab alone, or combined with tremelimumab, after chemoradiation keeps the cancer from returning and helps people live longer compared to a dummy treatment (placebo).